BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12:1033-1043. [PMID: 25074011 DOI: 10.1586/14787210.2014.940898] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther 2015;9:6083-94. [PMID: 26622169 DOI: 10.2147/DDDT.S80226] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
2 Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015;9:6083-6094. [PMID: 26622169 DOI: 10.2147/DDDT. S80226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Randolph JT, Flentge CA, Donner P, Rockway TW, Patel SV, Nelson L, Hutchinson DK, Mondal R, Mistry N, Reisch T, Dekhtyar T, Krishnan P, Pilot-Matias T, Stolarik DF, Beno DWA, Wagner R, Maring C, Kati WM. Discovery of fluorobenzimidazole HCV NS5A inhibitors. Bioorg Med Chem Lett 2016;26:5462-7. [PMID: 27780635 DOI: 10.1016/j.bmcl.2016.10.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Soriano V, Labarga P, de Mendoza C, Fernández-Montero JV, Esposito I, Benítez-Gutiérrez L, Peña JM, Barreiro P. New hepatitis C therapies for special patient populations. Expert Opin Pharmacother 2016;17:217-29. [PMID: 26595348 DOI: 10.1517/14656566.2016.1112790] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
5 Mody V, Ho J, Wills S, Mawri A, Lawson L, Ebert MCCJC, Fortin GM, Rayalam S, Taval S. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Commun Biol 2021;4:93. [PMID: 33473151 DOI: 10.1038/s42003-020-01577-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
6 Gentile I, Zappulo E, Buonomo AR, Maraolo AE, Borgia G. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs 2015;24:1111-21. [PMID: 26156630 DOI: 10.1517/13543784.2015.1059820] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
7 Buonomo AR, Scotto R, Nappa S, Arcopinto M, Salzano A, Marra AM, D'Assante R, Zappulo E, Borgia G, Gentile I. The role of curcumin in liver diseases. Arch Med Sci 2019;15:1608-20. [PMID: 31749891 DOI: 10.5114/aoms.2018.73596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Scotto R, Buonomo AR, De Pascalis S, Nerilli M, Pinchera B, Staiano L, Mercinelli S, Cattaneo L, Stanzione M, Stornaiuolo G, Martini S, Messina V, Coppola C, Coppola N, Gentile I. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results. Expert Rev Gastroenterol Hepatol 2021;15:1057-63. [PMID: 33573411 DOI: 10.1080/17474124.2021.1890029] [Reference Citation Analysis]
9 Gentile I, Zappulo E, Buonomo AR, Scotto R, Borgia G. Asunaprevir for hepatitis C: a safety evaluation. Expert Opin Drug Saf 2015;14:1631-46. [PMID: 26329454 DOI: 10.1517/14740338.2015.1084287] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
10 Jones BR, Howe AYM, Harrigan PR, Joy JB. The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus. Virus Evol 2018;4:vex041. [PMID: 29362671 DOI: 10.1093/ve/vex041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, Benítez-Gutiérrez L, Peña JM. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol 2015;11:333-41. [PMID: 25553890 DOI: 10.1517/17425255.2015.998997] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
12 Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015; 7(10): 1377-1389 [PMID: 26052383 DOI: 10.4254/wjh.v7.i10.1377] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 10.9] [Reference Citation Analysis]
13 Heil EL, Hynicka LM, Kottilil S, Tang L. What does the pharmacological future of treating chronic hepatitis C look like? Expert Rev Clin Pharmacol 2015;8:605-22. [PMID: 26289223 DOI: 10.1586/17512433.2015.1074859] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
14 Minaei AA, Kowdley KV. ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opin Pharmacother 2015;16:929-37. [PMID: 25800085 DOI: 10.1517/14656566.2015.1024653] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
15 Hathorn E, Elsharkawy AM. Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 2016;3:e000112. [PMID: 27752338 DOI: 10.1136/bmjgast-2016-000112] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
16 Farouk F, Wahba D, Mogawer S, Elkholy S, Elmeligui A, Abdelghani R, Ibahim S. Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients. Eur J Drug Metab Pharmacokinet 2020;45:89-99. [PMID: 31667795 DOI: 10.1007/s13318-019-00584-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
17 Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA. Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70:197-205. [PMID: 25246359 DOI: 10.1016/j.jinf.2014.09.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
18 Scotto R, Buonomo AR, Moriello NS, Maraolo AE, Zappulo E, Pinchera B, Gentile I, Borgia G. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. RRCT 2019;14:173-82. [DOI: 10.2174/1574887114666190306154650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]